亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial

免疫原性 肺炎球菌结合疫苗 医学 耐受性 肺炎球菌疫苗 人口 不利影响 结合疫苗 血清型 免疫学 抗原 内科学 儿科 肺炎链球菌 生物 微生物学 抗生素 环境卫生
作者
James Wassil,Maggie Sisti,Jeff Fairman,Matthew Davis,Carlos Fierro,Sean Bennett,Derek R. Johnson,Thi‐Sau Migone,Kien T. Nguyen,Paul Sauer,Michelle Currie,Sam Iki,Jakub K. Simon
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (3): 308-318 被引量:10
标识
DOI:10.1016/s1473-3099(23)00572-8
摘要

Summary

Background

Despite substantial reductions in pneumococcal disease with the availability of pneumococcal conjugate vaccines, a significant burden of pneumococcal disease remains due to the diversity of serotypes combined with serotype replacement. We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine), using cell-free protein synthesis to produce a variant of cross-reactive material 197 (eCRM) as the carrier protein, increasing serotype coverage while minimising carrier suppression. The aim of this clinical trial was to assess the safety, tolerability, and immunogenicity of three different doses of VAX-24 compared to pneumococcal 20-valent conjugate vaccine (PCV20).

Methods

This was a phase 1/2, randomised, double-masked study of VAX-24 versus PCV20 conducted in the USA. Key inclusion criteria included being a male or female aged 18 to 64 years in good health; key exclusion criteria included previous history of pneumococcal disease, receipt of a licensed or investigational pneumococcal vaccine, or immunosuppressive therapy. Participants were randomly allocated in a 1:1:1:1 ratio by permuted block to receive one dose of VAX-24 (1·1 μg of each antigen, 2·2 μg of each antigen, or 2·2 μg of 17 antigens mixed with 4·4 μg of seven antigens), or PCV20. The safety population included all participants with safety data. The immunogenicity population was as per-treatment in phase 2. Primary outcome measures included solicited and unsolicited adverse events. Secondary outcomes included serotype-specific opsonophagocytic activity (OPA) geometric mean titres (GMT), and IgG geometric mean concentrations (GMC) were measured 1 month postvaccination. Traditional non-inferiority criteria included OPA geometric mean ratio (GMR), with a lower bound of the two sided 95% CI of greater than 0·5 for shared serotypes. This completed trial is registered at ClinicalTrials.gov, NCT05266456.

Findings

Safety profiles were comparable among the treatment groups, with 170 of 209 participants (81%, 95% CI 75·2–86·2) to 178 of 207 participants (86%, 80·5–90·4) reporting at least one solicited adverse event among the three VAX-24 groups. 24 of 207 participants (12%, 7·6–16·8) to 32 of 209 of participants (15%, 10·7–20·9) experiened an unsolicited treatment emergent adverse event within 1 month postvaccination. VAX-24 2·2 μg met traditional OPA GMR non-inferiority criteria for all 20 shared serotypes; 16 serotypes elicited GMR point estimates greater than 1·0, and four reached the lower bound of the two-sided 95% CI greater than 1·0.

Interpretation

VAX-24 had a safety profile similar to PCV20 at all doses, with the 2·2 μg dose showing increased serotype coverage with decreased carrier suppression.

Funding

Vaxcyte.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英俊的铭应助科研通管家采纳,获得10
2秒前
2秒前
kd1412应助科研通管家采纳,获得10
2秒前
善学以致用应助吴昕昕采纳,获得10
4秒前
tingting9完成签到,获得积分10
6秒前
吾日三省吾身完成签到,获得积分10
11秒前
sola完成签到 ,获得积分10
26秒前
DreamMaker完成签到 ,获得积分10
28秒前
VVV完成签到,获得积分10
30秒前
43秒前
45秒前
_ban发布了新的文献求助10
48秒前
小黄鸭完成签到,获得积分10
52秒前
滴滴哒发布了新的文献求助10
59秒前
李李原上草完成签到 ,获得积分10
1分钟前
超级的千青完成签到 ,获得积分10
1分钟前
1分钟前
Bio应助又来注水了采纳,获得30
1分钟前
万能图书馆应助爹爹采纳,获得10
1分钟前
layman完成签到,获得积分10
1分钟前
郭郭完成签到 ,获得积分10
1分钟前
FL完成签到 ,获得积分10
1分钟前
科研通AI5应助sljzhangbiao11采纳,获得10
1分钟前
又来注水了完成签到,获得积分10
1分钟前
快乐海豚完成签到 ,获得积分10
1分钟前
科研通AI5应助科研通管家采纳,获得10
2分钟前
科研狗的春天完成签到 ,获得积分10
2分钟前
Lucas应助董可以采纳,获得10
2分钟前
2分钟前
Aqib发布了新的文献求助10
2分钟前
2分钟前
科研通AI5应助西瓜嘻嘻嘻采纳,获得10
2分钟前
吴昕昕发布了新的文献求助10
2分钟前
未晚完成签到 ,获得积分10
2分钟前
香蕉觅云应助Aqib采纳,获得10
2分钟前
早晨发布了新的文献求助10
2分钟前
孤鸿.完成签到 ,获得积分10
2分钟前
2分钟前
彭于晏应助11采纳,获得10
2分钟前
2分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990020
求助须知:如何正确求助?哪些是违规求助? 3532077
关于积分的说明 11256276
捐赠科研通 3270943
什么是DOI,文献DOI怎么找? 1805139
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228